Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-04-28 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
2023 年度独立董事述职报告（任涛）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2023" from Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the independent director's attendance at board and committee meetings, opinions on board resolutions, communication with auditors, and efforts to protect shareholder rights. The content focuses on the director's duties, oversight, and governance activities rather than financial results or audit opinions. The document length is 2675 characters, which is relatively short and does not contain financial statements or audit reports. It is a report by a board member about their activities and governance role, not an announcement or proxy solicitation. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or reports related to board or senior management activities.
2024-04-28 Chinese
2023 年度独立董事述职报告（郭霄峰）
Board/Management Information Classification · 95% confidence The document is titled '2023年度独立董事述职报告（郭霄峰）' which translates to '2023 Annual Independent Director's Work Report (Guo Xiaofeng)'. It is a detailed report by an independent director about his attendance, opinions, and activities during his tenure in 2023. The content includes meeting attendance, independent opinions on board resolutions, communication with auditors, and efforts to protect investor rights. It is a narrative report on the director's duties and performance rather than a financial report, audit report, or announcement. This type of document fits best under Board/Management Information (MANG), which covers announcements related to board members and senior management activities, including independent director reports. The document length is 2758 characters, which is not very short but contains substantive content about the director's role and activities. Therefore, the classification is MANG with high confidence.
2024-04-28 Chinese
2023年度审计报告
Regulatory Filings
2024-04-28 Chinese
中信建投证券股份有限公司关于广东永顺生物制药股份有限公司 2023 年募集资金存放与使用情况的专项核查意见
Regulatory Filings
2024-04-28 Chinese
董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the external auditor (Tianjian CPA Firm) for the company's 2023 annual audit. It details the auditor's background, the appointment process, meetings held with the auditor, and an overall evaluation of the auditor's performance and independence. The document does not contain the full annual report or the audit report itself but is a supervisory report on the audit process and auditor's conduct. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related supervisory information, excluding the full annual report. The document length is 1836 characters, which is short but contains substantive supervisory content rather than just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-28 Chinese
拟续聘2024年度会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (auditor) for the 2024 fiscal year. It details the auditor's background, audit fees, independence, and the approval process by the board and audit committee. There is no actual audit report or financial statements included, only information about the auditor appointment and related procedures. The document length is 2740 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, since it relates to audit matters but is not a full annual report or audit report itself. However, given the document is primarily an announcement of auditor reappointment and related information, it fits the Audit Report / Information category rather than Annual Report or Regulatory Filings. Confidence is high due to clear content focus on audit firm reappointment and audit-related disclosures. FY 2024
2024-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.